AN oral drop product has been voluntarily recalled from the market after it failed to meet product specifications, according to the Food and Drug Administration (FDA).
Recalled by the Cathay Drug Company Inc. were specific lots of “Cefixime 20 mg/mL granules for suspension (oral drops) [Triocef], 10 mL.”
Covered by the recall order are those with lot numbers and expiry dates 24A39/January 2026, 24B54/February 2026, 24C43/March 2026, 24E58/May 2026, and 24F66/June 2026.
The FDA said agency said the recalled products showed “inconsistencies in the as-say/potency test results” based on tests.
Cefixime is indicated for the treatment various illnesses such as acute bronchitis, acute exacerbation of chronic bronchitis, bronchiectasis with infection, secondary infections in chronic respiratory tract diseases, pneumonia., and urinary tract infections including pye-lonephritis, cystitis, and cystourethritis. It is also prescribed for uncomplicated gonorrhea (cervical/urethra), cholecystitis, chol-angitis, scarlet fever, sinusitis, tonsilitis, pharyngitis, otitis media, and typhoid fever (en-teric fever) including multi-drug-resistant typhoid fever.
